Black Cohosh
Black cohosh (Actaea racemosa) is a plant of the buttercup family from North America. Its root and rhizome are used in herbal preparations.
Also listed as Cimicifuga racemosa, Bugbane, Bugroot, Snakeroot
Which black cohosh preparations are used?
Clinical products are mostly dry extracts made with water and alcohol. The EU monograph covers three: an ethanol 58% extract (5.6 mg dry extract per day), an ethanol 60% extract (6.5 mg per day) and an isopropanol 40% extract (5 mg per day). The isopropanolic dose corresponds to about 40 mg of root per day. 1 2
Trials have also used other products, such as an ethanol extract standardized to 2.5% triterpene glycosides at 160 mg per day in the HALT trial. A study comparing about 40 mg and 127 mg per day found similar effects. 3 4
The extract in Remifemin, the most studied product; the EU monograph's preparation c). 1 3
Used at a dose equal to 40 mg herbal drug per day in German trials on symptoms and bone markers. 3 5
Covered by the EU monograph at 6.5 mg per day; one Austrian product was authorized in 2024 at 13 mg per day for moderate to severe symptoms. 2
Quality problems: wrong plant and unlisted herbs
Some black cohosh products have contained the wrong herb or mixtures with herbs not listed on the label. Adulteration with Asian Actaea species is considered the most plausible cause of the reported liver problems, though this is not proven. 3 8
Adulteration can be detected with methods such as microscopy, thin-layer chromatography and DNA barcoding. 3
In the EU, black cohosh is available as a licensed herbal medicine with a defined extract and dose. Licensed products state the extract type and amount, which supplements do not have to do in the same way. 1 6
Black cohosh is not blue cohosh
Blue cohosh (Caulophyllum thalictroides) is a different plant. It may raise blood pressure and blood sugar and cause chest pain, and its use to induce labor has been linked to life-threatening complications in infants. 8
Sources
- European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizoma (EMA/HMPC/48745/2017) European Medicines Agency, Committee on Herbal Medicinal Products, 2018
- Addendum to Assessment report on Cimicifuga racemosa (L.) Nutt., rhizoma (EMA/HMPC/8411/2025) European Medicines Agency, Committee on Herbal Medicinal Products, 2025
- Black Cohosh (PDQ), Health Professional Version (updated 10/31/2024) National Cancer Institute, 2024
- Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect Journal of Women's Health & Gender-Based Medicine (Liske et al.), 2002 · Study record
- Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study Menopause (Wuttke et al., Universität Göttingen), 2006
- Cimicifugae rhizoma: herbal medicinal product (summary for the public) European Medicines Agency, 2018
- Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms, an update on the evidence Climacteric (Castelo-Branco et al.), 2021
- Black Cohosh: Usefulness and Safety (last updated November 2024) National Center for Complementary and Integrative Health (NCCIH), 2024